Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate,
given in association with a fixed dose of cyclophosphamide (50 mg bid).